Clinical trials: Chronic Viral Hepatitis
Hepatitis C, Chronic, Hepatitis C
Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)
In patients with chronic hepatitis C, the ultimate treatment goal is the improvement of liver histology and inhibition of progression to liver cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- NCT00787371
- Testing
- PegIntron (peginterferon alfa-2b)
- Volunteers
- 69 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus (HCV)
Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genotype 1 - 6.
- Trial name
- NCT03341871
- Where
- Japan
- Volunteers
- 1,095 people
- Sponsor
- AbbVie
HIV Infections, Hepatitis C
Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
A study concerning viral kinetic with 10 co-infected HIV-HCV patients on treatment with peginterferon alfa-2a + ribavirin o IFN + ribavirin was reported in Conference on Retroviruses and Opportunistic Infections 2002 by Dr.
- Trial name
- NCT00612755
- Testing
- Peginterferon alfa-2a + ribavirin
- Where
- 19 sites in Spain
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Hospital Clinico Universitario San Cecilio
Hepatitis C
Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)
This is a two-part study of grazoprevir (MK-5172) + elbasvir (MK-8742) in Japanese participants with chronic hepatitis C virus (HCV) genotype 1 (GT1).
- Trial name
- NCT02203149
- Testing
- Grazoprevir, Elbasvir
- Volunteers
- 399 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Liver Diseases
Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)
The purpose of this study is to validate the first round HCV early dynamics discovery within a larger population.
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Interferon Deficiency
- Trial name
- sIFN-pred2 (NCT01760148)
- Testing
- interferon alpha 2b
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Junqi Niu
HCV Infection
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and activity of escalating, multiple, oral doses of GS-5885 in subjects with chronic genotype 1 Hepatitis C Virus (HCV) infection.
- Trial name
- NCT01193478
- Testing
- GS-5885
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gilead Sciences
Hepatitis C Viral, Chronic Kidney Disease stage3
A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir
The regimen using grazoprevir plus elbasvir treatment is promising in Japan, because it may safely be used for the elderly patients with renal dysfunction.
- Trial name
- NCT03144635
- Testing
- Grazoprevir plus Elbasvir
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Kyushu University
Chronic Hepatitis C
24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
Aim of the present study is to evaluate in a cohort of patients with genotype 2/3 chronic hepatitis C, relapsers to a previous PEG-IFN + ribavirin therapy (alpha-2a or alpha-2b) the efficacy of PEG-IFNα-2a + ribavirin…
- Trial name
- NCT01517308
- Testing
- pegylated interferon alpha 2a + ribavirin
- Where
- Italy
- Sponsor
- Federico II University
Viral Hepatitis
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
- Trial name
- NCT07128550
- Testing
- Tobevibart, Elebsiran, Bulevirtide
- Where
- 38 sites in Austria, France and 5 more
- Volunteers
- 150 people
- Sponsor
- Vir Biotechnology, Inc.
Hepatitis B, Chronic
Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients
This study evaluates generic emtricitabine(FTC) in Chinese naive children chronic hepatitis B patients. Single group of child patients were enrolled, which include HBeAg positive and negative Chronic hepatitis B(CHB)group.
- Trial name
- NCT02327676
- Testing
- Emtricitabine
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Asian-Pacific Alliance of Liver Disease, Beijing
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Hepatitis C, Chronic
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This prospective observational study will assess the insulin resistance and its impact on sustained virological response in patients with hepatitis C treated with Pegasys and Copegus.
- Trial name
- NCT01200225
- Where
- France
- Volunteers
- 1,155 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis c
Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model
Background and Aims: The prevalence of hepatitis C virus infection (HCV) infection in Punjab, India is 3.29%, with an estimated burden of around 650,000 viremic chronic HCV (CHC) patients.
- Trial name
- NCT03488485
- Testing
- Direct Acting Antivirals
- Where
- India
- Volunteers
- 50,000 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Hepatitis B
Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B
Hepatitis B virus (HBV) causes a wide spectrum of liver diseases, such as fulminant or acute hepatitis, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
- Trial name
- NCT00275938
- Testing
- interferon alpha 2b plus ribavirin
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C, Chronic
480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)
The purpose of this 12-week study was to assess in subjects with chronic hepatitis C (treatment-naïve, genotype 1) receiving weight-based doses of ribavirin the early virologic response to the 480 ug dose level of Locteron™…
- Trial name
- 480S (NCT00953589)
- Testing
- ribavirin
- Where
- 15 sites in Bulgaria, Israel and 1 more
- Volunteers
- 74 people
- Sponsor
- Biolex Therapeutics, Inc.
Chronic Hepatitis B, Mother-to-Child Transmission
Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B
To investigate the safety and efficacy of tenofovir alafenamide (orally 25 mg per day) treated in inactive chronic hepatitis B virus (HBV)-infected pregnant women with high viral load from the late pregnancy until the delivery…
- Conditions
- Chronic Hepatitis B, Mother-to-Child Transmission, Safety, Efficacy
- Trial name
- TAF-PPT (NCT04850950)
- Testing
- Tenofovir Alafenamide fumarate 25mg Oral Tablet
- Volunteers
- 240 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Hepatitis C
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone
This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with standard bi-therapy in patients with Hepatitis C chronic infection identified as non responders to the…
- Trial name
- Eclipse 2 (NCT01025297)
- Testing
- Interleukin-7
- Where
- 8 sites in France, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Cytheris SA
Chronic Hepatitis Delta
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants.
- Trial name
- NCT07096193
- Testing
- GS-4321
- Where
- 28 sites in United States, Bulgaria and 7 more
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
The primary objective of this registry study is to assess the durability of sustained virologic response (SVR) and clinical progression or regression of liver disease including the incidence of hepatocellular carcinoma following…
- Trial name
- NCT02292706
- Testing
- Sofosbuvir, Ribavirin, LDV/SOF
- Where
- 138 sites in United States, Australia and 8 more
- Volunteers
- 1,609 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options
The purpose of this early access protocol is to provide access to adefovir dipivoxil prior to its commercial availability to people with lamivudine-resistant chronic hepatitis B who have limited treatment options.
- Trial name
- NCT00042393
- Testing
- Adefovir Dipivoxil
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.